ReviewCurrent rheumatology reports2013
Autoantibodies in polymyositis and dermatomyositis.
Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 462 citations in OpenAlex.
- Diffuse Alveolar Haemorrhage as a Rare Pulmonary Manifestation of Antisynthetase Syndrome: A Case Series.Journal of clinical medicine · 2026Article
- Distinct phenotypes and prognosis between Jo-1 and non-Jo-1 subtypes in anti-synthetase syndrome: a retrospective cohort study from China.Clinical rheumatology · 2026Article
- Immune Myositis Complicating Follicular Lymphoma: Case Report.Reports (MDPI) · 2025Article
- Pulmonary Involvement in Patients with Positive Myositis Antibodies in Rheumatology: A Retrospective Monocentric Analysis.Journal of clinical medicine · 2025Article
- Dermatomyositis Masquerading Squamous Cell Carcinoma of the Maxilla (T1F1-γ and Ro-52 Positive): A Case Report and Review of Literature.Annals of Indian Academy of Neurology · 2025Article
- Anti-OJ antibody-positive anti-synthetase syndrome following SARS-CoV-2 infection: a case report and literature review.BMC rheumatology · 2024Article
- Clinical relevance of positively determined myositis antibodies in rheumatology: a retrospective monocentric analysis.Arthritis research & therapy · 2024Article
- Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy.Immunotherapy · 2024Review
- Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies.Diagnostics (Basel, Switzerland) · 2023Article
- Utility of Myositis-Specific Autoantibodies for Treatment Selection in Myositis.Current treatment options in rheumatology · 2022Article
- Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population.Frontiers in medicine · 2022Article
- How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.Immunologic research · 2021Article
- Generation and validation of recombinant antibodies to study human aminoacyl-tRNA synthetases.The Journal of biological chemistry · 2020Article
- Antisynthetase syndrome: A distinct disease spectrum.Journal of scleroderma and related disorders · 2020Review
- Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis.Journal of clinical laboratory analysis · 2020Article
- Polymyositis and dermatomyositis - challenges in diagnosis and management.Journal of translational autoimmunity · 2019Article
- Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies.Rheumatology international · 2019Article
- The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.Clinical rheumatology · 2019Article
- Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies.Frontiers in neurology · 2019Review
- Novel case of anti-synthetase syndrome.European journal of rheumatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory myopathies are a group of acquired diseases, characterized by immunoflogistic processes primarily involving the skeletal muscle. According to recent classification criteria, four major diseases have been identified: polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (IBM), and necrotizing autoimmune myositis (NAM). Autoantibodies can be found in the sera of most patients with myositis. Myositis-specific autoantibodies (MSAs) are markers of very specific disease entities within the spectrum of myositis, and target proteins involved in key processes of protein synthesis. Myositis autoantigens comprise the well-defined aminoacyl-tRNA synthetases, the Mi-2 helicase/histone deacetylase protein complex, and the signal recognition particle (SRP) ribonucleoprotein, together with novel targets such as TIF1-γ, MDA5, NXP2, SAE, and HMGCR. Recent studies suggest that autoantigens drive a B cell antigen-specific immune response in muscles. Interestingly, an increased expression of Jo-1 and Mi-2 in regenerating fibers in muscle biopsies from PM and DM patients compared to normal was demonstrated. Myositis autoantigen up-regulation was observed in neoplastic tissues, thus representing a potential link between cancer and autoimmunity in myositis. Non-immunological mechanisms seem to participate to the pathogenesis of inflammatory myopathies; induction of endoplasmic reticulum stress response in response to abnormal muscle regeneration and inflammation has recently been reported in patients with myositis. This review article provides an update of new emerging insights about the clinical and pathophysiologic role of principal autoantibodies in myositis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.